As of February 14, 2005, NeoGenesis Pharmaceuticals, Inc. was acquired by Schering-Plough Corp. NeoGenesis Pharmaceuticals, Inc., a drug discovery company, engages in the discovery and development of a portfolio of small molecule-based drugs focused on oncology and inflammation, both for itself and for its collaboration partners. Its core technology, the Automated Ligand Identification System (ALIS), is an universal affinity-based system for identifying and optimizing novel drug leads. Together with the company’s NeoMorph compound library, consisting of approximately 10 million diverse medicinally relevant small molecules, ALIS enables the identification of novel and selective drug leads against validated and emerging new genomic targets. The company has partnerships and collaborative research agreements with various biotechnology and pharmaceutical companies, including Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough, and Tularik.